Tonix Pharmaceuticals Holding Corp.

NasdaqGS:TNXP Stock Report

Market Cap: US$196.7m

Tonix Pharmaceuticals Holding Future Growth

Future criteria checks 2/6

Tonix Pharmaceuticals Holding is forecast to grow earnings and revenue by 27.2% and 42.7% per annum respectively while EPS is expected to grow by 50.9% per annum.

Key information

27.2%

Earnings growth rate

50.87%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate42.7%
Future return on equityn/a
Analyst coverage

Low

Last updated29 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jun 29

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Summary Tonix Pharmaceuticals remains rated Hold as Tonmya's commercial launch underwhelms, with Q1 2026 net product revenue at $3.7m, arguably below expectations. TNXP's cash runway is limited, with $185.5m on hand and quarterly net losses exceeding $40m, raising future funding concerns. Competitive pressure and uncertain pipeline prospects, including MDD and Lyme disease candidates, temper confidence in TNXP's ability to drive meaningful upside. I maintain a Hold, seeing limited near-term catalysts but potential upside if Tonmya sales accelerate or pipeline assets deliver unexpected positive data. Read the full article on Seeking Alpha
Analysis Article • Dec 01

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Aug 14

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...

Earnings and Revenue Growth Forecasts

NasdaqGS:TNXP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028163-85-170-1374
12/31/202779-152-205-1524
12/31/202634-170-200-1444
3/31/202618-147-131-126N/A
12/31/202513-124-103-100N/A
9/30/202510-99-76-75N/A
6/30/202510-81-65-65N/A
3/31/202510-132-60-60N/A
12/31/202410-130-61-61N/A
9/30/202411-135-69-69N/A
6/30/202412-149-76-73N/A
3/31/202410-99-91-87N/A
12/31/20238-117-110-102N/A
9/30/20234-123-114-102N/A
6/30/2023N/A-124-121-102N/A
3/31/2023N/A-123-132-100N/A
12/31/2022N/A-117-146-98N/A
9/30/2022N/A-112-167-98N/A
6/30/2022N/A-102-156-88N/A
3/31/2022N/A-98-141-86N/A
12/31/2021N/A-92-111-76N/A
9/30/2021N/A-80-81-67N/A
6/30/2021N/A-73-80-69N/A
3/31/2021N/A-64-69-60N/A
12/31/2020N/A-52-57-49N/A
9/30/2020N/A-46-45-41N/A
6/30/2020N/A-42-33-33N/A
3/31/2020N/A-34-27-27N/A
12/31/2019N/A-31N/A-27N/A
9/30/2019N/A-31N/A-27N/A
6/30/2019N/A-28N/A-25N/A
3/31/2019N/A-29N/A-26N/A
12/31/2018N/A-29N/A-24N/A
9/30/2018N/A-24N/A-22N/A
6/30/2018N/A-24N/A-22N/A
3/31/2018N/A-23N/A-21N/A
12/31/2017N/A-21N/A-19N/A
9/30/2017N/A-23N/A-20N/A
6/30/2017N/A-25N/A-23N/A
3/31/2017N/A-30N/A-27N/A
12/31/2016N/A-39N/A-37N/A
9/30/2016N/A-45N/A-44N/A
6/30/2016N/A-50N/A-48N/A
3/31/2016N/A-52N/A-49N/A
12/31/2015N/A-48N/A-43N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNXP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TNXP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TNXP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TNXP's revenue (42.7% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: TNXP's revenue (42.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TNXP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 22:52
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tonix Pharmaceuticals Holding Corp. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Chiara RussoBrean Capital Historical (Janney Montgomery)
David BuckB. Riley Securities, Inc.